HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
Daniel I. Swerdlow(Silence Therapeutics (United Kingdom)), Rudi G. J. Westendorp(University of Copenhagen), Niek Verweij(Regeneron (United States)), Robert A. Scott(Age UK), Karoline Kuchenbaecker(University of Cambridge), P. Johnson(University of Glasgow), Yiran Guo(BGI Group (China)), Ioanna Tzoulaki(Academy of Athens), Jorgen Engmann(Farr Institute), Miglė Bacevičienė(Lithuanian Sports University), KaWah Li(University College London), Anne Peasey(University College London), Claudia Giambartolomei(University College London), Urszula Stepaniak(Jagiellonian University), Sofia Malyutina(Research Institute of Therapy and Preventive Medicine), David Preiss(Medical Research Council), N. Charlotte Onland‐Moret(St. Elizabeth's Hospital), Ulf dé Fairé(Karolinska Institutet), Daphne L. van der A(National Institute for Public Health and the Environment), Bengt Sennblad(Science for Life Laboratory), Marlene Stewart(University of Edinburgh), Reecha Sofat(University College London), Stephen J. Sharp(University of Cambridge), Fabrizio Veglia, Yvonne T. van der Schouw(University Medical Center Utrecht), Michael V. Holmes(University of Oxford), Andrzej Pająk(Jagiellonian University), Antoinette Amuzu, Tina Shah(Farr Institute), John Gallacher(Cardiff University), Fotios Drenos(University College London), Nita G. Forouhi(University of Cambridge), Philip Howard(University College London), Damiano Baldassarre(University of Milan), Maarten Leusink(Utrecht University), Sarah G. Buxbaum(Jackson State University), Renate B. Schnabel(Universität Hamburg), Stefan Stender(Copenhagen University Hospital), Jaroslav A. Hubáček(Institute of Clinical and Experimental Medicine), Christina Lee Chung(University College London), Gordon Lowe(University of Glasgow), Růžena Kubínová(National Institute of Public Health), Jackie A. Cooper(University College London), Abdonas Tamošiūnas, Jutta Palmen(University College London), Romanvan Topor-Madry(Jagiellonian University), Elena Tremoli(Maria Cecilia Hospital), Ian Ford(University of Glasgow), J. Wouter Jukema(Leiden University Medical Center)
Cited by 709
Related Papers
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
|The Lancet|2002|5.4k
Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants
|The Lancet|2016|4.4k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k